Bone morphogenetic proteins and receptors are over-expressed in bone-marrow cells of multiple myeloma patients and support myeloma cells by inducing ID genes

Leukemia Research

Volumn 34, Issue 6, 2010, Pages 742-751

  Grčević, Danka ^a   Kušec, Rajko ^b   Kovačić, Nataša ^a   Lukić, Anita ^a   Lukić, Ivan Krešimir ^a,c   Ivčević, Sanja ^a   Nemet, Damir ^d   Seiwerth, Ranka Serventi ^d   Ostojić, Slobodanka Kolonić ^e   Croucher, Peter I ^f   Marušić, Ana ^a,g  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b University of Zagreb School of Medicine   (Croatia)

^c Biosistemi doo   (Croatia)

^d KBC Zagreb   (Croatia)

^e University of Zagreb   (Croatia)

^f UNIVERSITY OF SHEFFIELD   (United Kingdom)

^g UNIVERSITY OF SPLIT   (Croatia)

Author keywords

Bone morphogenetic proteins; Bone marrow; Cell lines; Cell survival; ID genes; Multiple myeloma

Indexed keywords

ACTIVIN RECEPTOR; ACTIVIN RECEPTOR 1; ACTIVIN RECEPTOR 2A; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 6; BONE MORPHOGENETIC PROTEIN RECEPTOR; BORTEZOMIB; CYCLIN DEPENDENT KINASE INHIBITOR 1A; INHIBITOR OF DIFFERENTIATION 1; INHIBITOR OF DIFFERENTIATION 2; INTERLEUKIN 6; NOGGIN; PROTEIN BAX; SMAD6 PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL SURVIVAL; CONTROLLED STUDY; DISEASE MARKER; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; ONCOGENE; PATHOPHYSIOLOGY; PLASMA CELL; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW CELLS; BONE MORPHOGENETIC PROTEIN RECEPTORS; BONE MORPHOGENETIC PROTEINS; CASE-CONTROL STUDIES; CELL PROLIFERATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF DIFFERENTIATION PROTEINS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 77952095269     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.10.016     Document Type: Article

References (49)

1. Barlogie B., Shaughnessy J., Tricot G., Jacobson J., Zangari M., Anaissie E., et al. Treatment of multiple myeloma. Blood 2004, 103:20-32.
2. Hideshima T., Mitsiades C., Tonon G., Richardson P.G., Anderson K.C. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007, 7:585-598.
3. Kyle R.A., Rajkumar S.V. Multiple myeloma. Blood 2008, 111:2962-2972.
4. Chen Q., Ray S., Hussein M.A., Srkalovic G., Almasan A. Role of Apo2L/TRAIL and Bcl-2-family proteins in apoptosis of multiple myeloma. Leuk Lymphoma 2003, 44:1209-1214.
5. Yang D.H., Park J.S., Jin C.J., Kang H.K., Nam J.H., Rhee J.H., et al. The dysfunction and abnormal signaling pathway of dendritic cells loaded by tumor antigen can be overcome by neutralizing VEGF in multiple myeloma. Leuk Res 2009, 33:665-670.
6. van de Donk N.W., Lokhorst H.M., Bloem A.C. Growth factors and antiapoptotic signaling pathways in multiple myeloma. Leukemia 2005, 19:2177-2185.
7. Lauta V.M. A review of the cytokine network in multiple myeloma. Cancer 2003, 97:2440-2452.
8. Oliveira A.M., Maria D.A., Metzger M., Linardi C., Giorgi R.R., Moura F., et al. Thalidomide treatment down-regulates SDF-1alpha and CXCR4 expression in multiple myeloma patients. Leuk Res 2009, 33:970-973.
9. Bommert K., Bargou R.C., Stühmer T. Signalling and survival pathways in multiple myeloma. Eur J Cancer 2006, 42:1574-1580.
10. Fukuda N., Saitoh M., Kobayashi N., Miyazono K. Execution of BMP-4-induced apoptosis by p53-dependent ER dysfunction in myeloma and B-cell hybridoma cells. Oncogene 2006, 25:3509-3517.
11. Kawamura C., Kizaki M., Yamato K., Uchida H., Fukuchi Y., Hattori Y., et al. Bone morphogenetic protein-2 induces apoptosis in human myeloma cells with modulation of STAT3. Blood 2000, 96:2005-2011.
12. Rø T.B., Holt R.U., Brenne A.T., Hjorth-Hansen H., Waage A., Hjertner O., et al. Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells. Oncogene 2004, 23:3024-3032.
13. Hjerner O., Hjorth-Hansen H., Børset M., Seidel C., Waage A., Sundan A. Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells. Blood 2001, 97:516-522.
14. Kawamura C., Kizaki M., Ikeda Y. Bone morphogenetic protein (BMP)-2 induces apoptosis in human myeloma cells. Leuk Lymphoma 2002, 43:635-639.
15. Clement J.H., Raida M., Sänger J., Bicknell R., Liu J., Naumann A., et al. Bone morphogenetic protein 2 (BMP-2) induces in vitro invasion and in vivo hormone independent growth of breast carcinoma cells. Int J Oncol 2005, 27:401-407.
16. Deng H., Mikizumi R., Ravikumar T.S., Dong H., Yang W., Yang W.L. Bone morphogenetic protein-4 is overexpressed in colonic adenocarcinomas and promotes migration and invasion of HCT116 cells. Exp Cell Res 2007, 313:1033-1044.
17. Ide H., Yoshida T., Matsumoto N., Aoki K., Osada Y., Sugimura T., et al. Growth regulation of human prostate cancer cells by bone morphogenetic protein-2. Cancer Res 1997, 57:5022-5027.
18. Langenfeld E.M., Bojnowski J., Perone J., Langenfeld J. Expression of bone morphogenetic proteins in human lung carcinomas. Ann Thorac Surg 2005, 80:1028-1032.
19. Rosenwald A., Wright G., Chan W.C., Connors J.M., Campo E., Fisher R.I., et al. Lymphoma/leukemia molecular profiling project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. New Engl J Med 2002, 346:1937-1947.
20. Rothhammer T., Poser I., Soncin F., Bataille F., Moser M., Bosserhoff A.-K. Bone morphogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration. Cancer Res 2005, 65:448-456.
21. Zlei M., Egert S., Wider D., Ihorst G., Wäsch R., Engelhardt M. Characterization of in vitro growth of multiple myeloma cells. Exp Hematol 2007, 35:1550-1561.
22. Chen D., Zhao M., Mundy G.R. Bone morphogenetic proteins. Growth Factors 2004, 22:233-241.
23. Herpin A., Cunningham C. Cross-talk between the bone morphogenetic protein pathway and other major signaling pathways results in tightly regulated cell-specific outcomes. FEBS J 2007, 274:2977-2985.
24. Bhatia M., Bonnet D., Wu D., Murdoch B., Wrana J., Gallacher L., et al. Bone morphogenetic proteins regulate the developmental program of human hematopoietic stem cells. J Exp Med 1999, 189:1139-1147.
25. Edwards C.M., Zhuang J., Mundy G.R. The pathogenesis of the bone disease of multiple myeloma. Bone 2008, 42:1007-1013.
26. Lasorella A., Uo T., Iavarone A. Id proteins at the cross-road of development and cancer. Oncogene 2001, 20:8326-8333.
27. Norton J.D. ID helix-loop-helix proteins in cell growth, differentiation and tumorigenesis. J Cell Sci 2000, 113:3897-3905.
28. Ruzinova M.B., Benezra R. Id proteins in development, cell cycle and cancer. Trends Cell Biol 2003, 13:410-418.
29. Fong S., Itahana Y., Sumida T., Singh J., Coppe J.P., Liu Y., et al. Id-1 as a molecular target in therapy for breast cancer cell invasion and metastasis. Proc Natl Acad Sci USA 2003, 100:13543-13548.
30. INK4a/pRB pathway. Carcinogenesis 2002, 23:721-725.
31. Dicato M., Boccadoro M., Cavenagh J., Harousseau J.L., Ludwig H., San Miguel J., et al. Management of multiple myeloma with bortezomib: experts review the data and debate the issues. Oncology 2006, 70:474-482.
32. Shipman C.M., Croucher P.I. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 2003, 63:912-916.
33. Smith A., Wisloff F., Samson D. UK Myeloma Forum; Nordic Myeloma Study Group; British Committee for Standards in Haematology. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 2006, 132:410-451.
34. Durie B.G., Salmon S.E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975, 36:842-854.
35. Human Genome Organisation (HUGO). Gene Nomenclature Committee: Guidelines for Human Gene Nomenclature. Available from: http://www.genenames.org/guidelines.html.
36. Grcevic D., Lukic I.K., Kovacic N., Ivcevic S., Katavic V., Marusic A. Activated T lymphocytes suppress osteoclastogenesis by diverting early monocyte/macrophage progenitor lineage commitment towards dendritic cell differentiation through down-regulation of receptor activator of nuclear factor-kappaB and c-Fos. Clin Exp Immunol 2006, 146:146-158.
37. Maddika S., Ande S.R., Panigrahi S., Paranjothy T., Weglarczyk K., Zuse A., et al. Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Updat 2007, 10:13-29.
38. Danial N.N., Korsmeyer S.J. Cell death: critical control points. Cell 2004, 116:205-219.
39. Bickel D.R. Degrees of differential gene expression: detecting biologically significant expression differences and estimating their magnitudes. Bioinformatics 2004, 20:682-688.
40. Neri P., Tassone P., Shammas M., Yasui H., Schipani E., Batchu R.B., et al. Biological pathways and in vivo antitumor activity induced by Atiprimod in myeloma. Leukemia 2007, 21:2519-2526.
41. Zhan F., Barlogie B., Arzoumanian V., Huang Y., Williams D.R., Hollmig K., et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 2007, 109:1692-1700.
42. Mattioli M., Agnelli L., Fabris S., Baldini L., Morabito F., Bicciato S., et al. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene 2005, 24:2461-2473.
43. Detmer K., Steele T.A., Shoop M.A., Dannawi H. Lineage-restricted expression of bone morphogenetic protein genes in human hematopoietic cell lines. Blood Cells Mol Dis 1999, 25:310-323.
44. Grcevic D., Marusic M., Grahovac B., Jaksic B., Kusec R. Expression of bone morphogenetic proteins in acute promyelocytic leukemia before and after combined all trans-retinoic acid and cytotoxic treatment. Leuk Res 2003, 27:731-738.
45. Langenfeld E.M., Kong Y., Langenfeld J. Bone morphogenetic protein 2 stimulation of tumor growth involves the activation of Smad-1/5. Oncogene 2002, 25:685-692.
46. Krejčí J., Harničarová A., Streitová D., Hájek R., Pour L., Kozubek S., et al. Epigenetics of multiple myeloma after treatment with cytostatics and gamma radiation. Leuk Res 2009, 33:1490-1498.
47. Kameda T., Koike C., Saitoh K., Kuroiwa A., Iba H. Developmental patterning in chondrocytic cultures by morphogenic gradients: BMP induces expression of Indian hedgehog and noggin. Genes Cells 1999, 4:175-184.
48. Hudlebusch H.R., Theilgaard-Mönch K., Lodahl M., Johnsen H.E., Rasmussen T. Identification of ID-1 as a potential target gene of MMSET in multiple myeloma. Br J Haematol 2005, 130:700-708.
49. Schwarze M.M., Hawley R.G. Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin 6-mediated up-regulation of bcl-xL. Cancer Res 1995, 55:2262-2265.